South San Francisco, Calif. — October 19, 2025 — Leads & Copy — RAPT Therapeutics, Inc. (Nasdaq: RAPT) plans to report topline data from the Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU). The trial was conducted by Shanghai Jeyou Pharmaceutical Co., Ltd. (Jeyou), formerly called Shanghai Jemincare Pharmaceutical Co., Ltd.
RAPT will host a webcast conference call with a slide presentation on Monday, October 20, 2025, at 8:30 a.m. ET. To join the call via phone and participate in the Q&A, pre-register online to receive a telephone number and passcode. The live webcast and audio archive can be accessed on the RAPT Therapeutics website.
RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for inflammatory and immunological diseases.
RAPT Investor Contact: Sylvia Wheeler, swheeler@wheelhouselsa.com
RAPT Media Contact: Aljanae Reynolds, areynolds@wheelhouselsa.com
Source: RAPT Therapeutics, Inc.
